top of page


The COFFI Consumer Advisory Committee (CAC) represents consumer perspectives within the COFFI Collaborative. The CAC met informally in December 2021 to reflect on consumer priorities and refined three broad areas and questions that they would like information from the scientists - either through what they know from the field and what their research is beginning to show.

The three topics explored in the workshop were:

1. The illness trajectory

2. Mind-body explanations of the symptoms

3. What helps people recover

The aim of the virtual workshop was to:

  • Help develop narratives from science that are useful for consumers

  • To help scientists draw on the consumer viewpoint in developing, designing and disseminating their research

  • The questions posed are a guide to initiate the dialogue, the format is experimental, but we hope this approach can be finessed over time

COFFI Consumer workshop flyer
Download PDF • 184KB

Further details and recording have been uploaded in the COFFI members portal.

The upcoming European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) will take place in Copenhagen, Denmark, on 15-18 April 2023. In addition to the main live congress, the Scientific Programme of ECCMID 2023 will consist of live-streamed, online-only events with topics in the fields of clinical microbiology and infectious diseases.

We are proud to announce the following speakers who will represent COFFI in a 2-hour Symposium titled "Post-Infective fatigue syndromes and long-COVID: similarities and differences" on the 17th of April, 2023.

Talk title: Prevalence and natural history of post-infective fatigue in adults and children

Speaker: Ben Katz, United States

Talk title: Pathophysiology of post-infective fatigue states

Speaker: Ruud Raijmakers, Netherlands

Talk title: Pathophysiology of long-COVID

Speaker: Knut Stavem, Norway

The ECCMID Scientific Programme can be found here:

Updated: Nov 15, 2022

Health‑related quality of life among persons with initial mild, moderate, and severe or critical COVID‑19 at 1 and 12 months after infection: a prospective cohort study

Anouk Verveen1,2, Elke Wynberg3,4,5†, Hugo D. G. van Willigen4,5,6†, Udi Davidovich3,7, Anja Lok2,8,9, Eric P. Moll van Charante2,10,11, Menno D. de Jong5,6, Godelieve de Bree4,5, Maria Prins3,4,5, Hans Knoop1,2, Pythia T. Nieuwkerk1,2,5*   and the RECoVERED Study Group


bottom of page